Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

OLMA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 19.40%

Insider Buying (Last 12 Months): $3,031,235.30

Insider Selling (Last 12 Months): $37,666,748.28

Olema Pharmaceuticals Insider Trading History Chart

Olema Pharmaceuticals Share Price & Price History

^$8.78

▲ +0.91 (11.56%)

As of 11/22/2024 01:00 AM ET

Days: 30 | 90 | 365

I was wrong. Dead wrong.

From Porter & Company | Ad

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

Olema Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/1/2024	Biocapital Advisors L Paradigm	Major Shareholder	Sell	2,400,000	$14.91	$35,784,000.00	783,118
7/29/2024	Cyrus Harmon	Director	Sell	4,066	$15.58	$63,348.28	752,217
7/11/2024	Cyrus Harmon	Director	Sell	5,000	$12.26	$61,300.00	756,283
6/28/2024	Cyrus Harmon	Director	Sell	20,000	$10.77	$215,400.00	761,283
6/3/2024	Cyrus Harmon	Director	Sell	5,000	$10.93	$54,650.00	786,283
5/31/2024	Cyrus Harmon	Director	Sell	15,000	$9.41	$141,150.00	791,283
5/6/2024	Cyrus Harmon	Director	Sell	5,000	$10.92	$54,600.00	806,283
4/30/2024	Cyrus Harmon	Director	Sell	15,000	$9.51	$142,650.00	811,283
3/28/2024	Cyrus Harmon	Director	Sell	20,000	$10.97	$219,400.00	826,283
2/29/2024	Cyrus Harmon	Director	Sell	25,000	$12.41	$310,250.00	846,283
1/31/2024	Cyrus Harmon	Director	Sell	25,000	$12.23	$305,750.00	876,283
12/6/2023	Biocapital Advisors L Paradigm	Major Shareholder	Buy	100,000	$11.60	$1,160,000.00	6,590,981
12/5/2023	G. Walmsley Graham	Director	Buy	131,870	$14.19	$1,871,235.30	1,800,000
11/30/2023	Cyrus Harmon	Director	Sell	25,000	$12.57	$314,250.00	926,283
11/21/2023	Cyrus Harmon	Director	Sell	4,192	$14.86	$62,293.12	955,272
11/21/2023	Naseem Zojwalla	Insider	Sell	7,461	$14.84	$110,721.24	37,759
11/21/2023	Sean Bohen	CEO	Sell	29,293	$14.88	$435,879.84	172,857
11/8/2023	David C Myles	Insider	Sell	200	$17.61	$3,522.00	561,270
11/3/2023	David C Myles	Insider	Sell	541	$17.51	$9,472.91	561,470
11/2/2023	Cyrus Harmon	Director	Sell	5,000	$15.64	$78,200.00	943,714
11/1/2023	David C Myles	Insider	Sell	6,668	$15.02	$100,153.36	565,343
10/31/2023	Cyrus Harmon	Director	Sell	25,000	$12.05	$301,250.00	948,714
9/29/2023	Cyrus Harmon	Director	Sell	25,000	$12.41	$310,250.00	973,714
9/19/2023	David C Myles	Insider	Sell	20,000	$12.67	$253,400.00	572,011
9/12/2023	Bvf Partners L P/Il	Director	Buy	1,505,932	$9.84	$14,818,370.88	4,688,954
9/5/2023	Cyrus Harmon	Director	Sell	10,000	$11.62	$116,200.00	998,714
8/31/2023	Cyrus Harmon	Director	Sell	15,000	$9.36	$140,400.00	1,008,714
6/8/2023	Cyrus Harmon	Director	Sell	10,000	$6.30	$63,000.00	1,038,714
6/5/2023	Cyrus Harmon	Director	Sell	5,000	$6.04	$30,200.00	1,053,714
6/10/2022	Bvf Partners L P/Il	Director	Buy	200,000	$4.03	$806,000.00	3,913,676
3/10/2022	Kinney Horn	Insider	Sell	5,253	$4.75	$24,951.75
1/10/2022	Kinney Horn	Insider	Sell	5,251	$6.85	$35,969.35
12/10/2021	Kinney Horn	Insider	Sell	5,251	$10.39	$54,557.89
11/30/2021	Bvf Partners L P/Il	Director	Buy	739,675	$9.39	$6,945,548.25
11/29/2021	Cyrus Harmon	CTO	Sell	400	$24.76	$9,904.00

9 hidden AI stocks set to thrive in Trump’s new era

From StockEarnings | Ad

AI ETFs are Booming, But These 9 AI Stocks are Better Plays By 2030, the AI industry is projected to be worth trillions of dollars (here’s how to tap into this new wealth)

Get the Name of These AI Picks Now

SEC Filings (Institutional Ownership Changes) for Olema Pharmaceuticals (NASDAQ:OLMA)

91.78% of Olema Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Olema Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/19/2024	Barclays PLC	94,915	$1.13M	0.0%	+105.0%	0.166%
11/16/2024	Geode Capital Management LLC	934,929	$11.17M	0.0%	-11.8%	1.632%
11/15/2024	Conway Capital Management Inc.	10,000	$0.12M	0.1%	N/A	0.017%
11/15/2024	Barclays PLC	94,915	$1.13M	0.0%	+105.0%	0.166%
11/15/2024	XTX Topco Ltd	25,332	$0.30M	0.0%	+103.4%	0.044%
11/15/2024	EP Wealth Advisors LLC	48,655	$0.58M	0.0%	+5.2%	0.085%
11/15/2024	Wellington Management Group LLP	1,002,685	$11.97M	0.0%	+10.8%	1.750%
11/15/2024	State Street Corp	1,969,963	$23.52M	0.0%	+1.1%	3.438%
11/15/2024	Point72 Asset Management L.P.	3,687,374	$44.03M	0.1%	+14.8%	6.435%
11/15/2024	Ikarian Capital LLC	92,000	$1.10M	0.1%	N/A	0.161%
11/15/2024	Jacobs Levy Equity Management Inc.	74,919	$0.90M	0.0%	-14.3%	0.131%
11/15/2024	Janus Henderson Group PLC	17,800	$0.21M	0.0%	-68.2%	0.031%
11/15/2024	HighVista Strategies LLC	212,185	$2.53M	0.9%	-14.4%	0.370%
11/14/2024	Portland Investment Counsel Inc.	12,000	$0.14M	0.1%	N/A	0.021%
11/14/2024	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	75,974	$0.91M	0.0%	-9.1%	0.133%
11/13/2024	Great Point Partners LLC	1,000,000	$11.94M	3.5%	+25.5%	1.746%
11/13/2024	Dynamic Technology Lab Private Ltd	19,894	$0.24M	0.0%	N/A	0.035%
11/12/2024	Pitcairn Co.	24,546	$0.29M	0.0%	-9.1%	0.043%
11/12/2024	Charles Schwab Investment Management Inc.	330,761	$3.95M	0.0%	+168.5%	0.578%
11/9/2024	Intech Investment Management LLC	13,686	$0.16M	0.0%	N/A	0.024%
11/5/2024	Victory Capital Management Inc.	851,512	$10.17M	0.0%	+9.9%	1.487%
10/25/2024	China Universal Asset Management Co. Ltd.	11,014	$0.13M	0.0%	+67.6%	0.019%
10/23/2024	Hennion & Walsh Asset Management Inc.	117,595	$1.40M	0.1%	+34.7%	0.205%
10/3/2024	SG Americas Securities LLC	13,056	$0.16M	0.0%	N/A	0.023%
9/16/2024	Cubist Systematic Strategies LLC	13,416	$0.15M	0.0%	N/A	0.024%
8/27/2024	Dana Investment Advisors Inc.	74,657	$0.81M	0.0%	N/A	0.133%
8/15/2024	Susquehanna Portfolio Strategies LLC	26,549	$0.29M	0.0%	-23.3%	0.047%
8/15/2024	The Manufacturers Life Insurance Company	15,888	$0.17M	0.0%	+52.2%	0.028%
8/15/2024	Deerfield Management Company L.P. Series C	31,405	$0.34M	0.0%	N/A	0.056%
8/15/2024	Affinity Asset Advisors LLC	275,000	$2.98M	0.3%	N/A	0.492%
8/14/2024	Squarepoint Ops LLC	57,070	$0.62M	0.0%	-22.4%	0.102%
8/14/2024	Point72 Asset Management L.P.	3,211,927	$34.75M	0.1%	N/A	5.742%
8/14/2024	Cubist Systematic Strategies LLC	13,416	$0.15M	0.0%	N/A	0.024%
8/14/2024	Great Point Partners LLC	796,880	$8.62M	1.7%	N/A	1.425%
8/14/2024	Marshall Wace LLP	588,996	$6.37M	0.0%	+7.5%	1.053%
8/14/2024	Logos Global Management LP	3,208,875	$34.72M	2.8%	-26.8%	5.737%
8/14/2024	Profund Advisors LLC	18,908	$0.21M	0.0%	-58.2%	0.034%
8/13/2024	Ensign Peak Advisors Inc	14,849	$0.16M	0.0%	+6.1%	0.027%
8/12/2024	XTX Topco Ltd	12,454	$0.14M	0.0%	-53.8%	0.022%
8/9/2024	Renaissance Technologies LLC	53,200	$0.58M	0.0%	N/A	0.095%
8/9/2024	Dimensional Fund Advisors LP	1,684,924	$18.23M	0.0%	-13.0%	3.012%
8/8/2024	American Century Companies Inc.	11,832	$0.13M	0.0%	-70.4%	0.021%
8/7/2024	ClariVest Asset Management LLC	63,149	$0.68M	0.1%	+3.1%	0.113%
8/6/2024	Candriam S.C.A.	1,058,673	$11.45M	0.1%	+199.9%	1.893%
8/5/2024	Victory Capital Management Inc.	774,792	$8.38M	0.0%	+26.9%	1.385%
8/1/2024	Rhumbline Advisers	59,261	$0.64M	0.0%	+43.5%	0.106%
7/26/2024	Bank of New York Mellon Corp	139,923	$1.51M	0.0%	+72.1%	0.250%
7/20/2024	Hennion & Walsh Asset Management Inc.	87,312	$0.95M	0.0%	N/A	0.156%
5/16/2024	California State Teachers Retirement System	34,695	$0.39M	0.0%	+3.4%	0.062%
5/16/2024	Jacobs Levy Equity Management Inc.	74,919	$0.85M	0.0%	-49.9%	0.134%
5/16/2024	Janus Henderson Group PLC	1,221,662	$13.82M	0.0%	+74.5%	2.184%
5/15/2024	Price T Rowe Associates Inc. MD	26,251	$0.30M	0.0%	+6.0%	0.047%
5/14/2024	EntryPoint Capital LLC	14,530	$0.16M	0.1%	+949.9%	0.026%
5/10/2024	Acadian Asset Management LLC	103,179	$1.17M	0.0%	-59.7%	0.184%
5/10/2024	Vanguard Group Inc.	2,407,688	$27.26M	0.0%	-11.0%	4.305%
5/8/2024	Entropy Technologies LP	14,246	$0.16M	0.0%	N/A	0.025%
5/7/2024	Susquehanna Fundamental Investments LLC	15,565	$0.18M	0.0%	N/A	0.028%
5/7/2024	Susquehanna Portfolio Strategies LLC	34,608	$0.39M	0.0%	-4.9%	0.062%
5/7/2024	Swiss National Bank	70,300	$0.80M	0.0%	+8.8%	0.126%
5/7/2024	ClariVest Asset Management LLC	61,268	$0.69M	0.1%	-9.2%	0.110%
5/1/2024	Mirae Asset Global Investments Co. Ltd.	10,539	$0.12M	0.0%	-33.9%	0.019%
4/29/2024	China Universal Asset Management Co. Ltd.	10,562	$0.12M	0.0%	+66.6%	0.019%
2/26/2024	Perceptive Advisors LLC	539,831	$7.57M	0.2%	N/A	0.980%
2/14/2024	First Light Asset Management LLC	631,064	$8.85M	0.7%	N/A	1.145%
2/14/2024	Sectoral Asset Management Inc.	19,230	$0.27M	0.1%	-95.6%	0.035%
2/7/2024	Dimensional Fund Advisors LP	1,715,420	$24.07M	0.0%	+1.3%	3.113%
2/7/2024	Jump Financial LLC	19,866	$0.28M	0.0%	N/A	0.036%
2/6/2024	Swiss National Bank	64,600	$0.91M	0.0%	N/A	0.117%
2/5/2024	Victory Capital Management Inc.	621,527	$8.72M	0.0%	+879.6%	1.128%
1/30/2024	Zurcher Kantonalbank Zurich Cantonalbank	9,282	$0.13M	0.0%	N/A	0.017%
1/24/2024	Mirae Asset Global Investments Co. Ltd.	15,951	$0.22M	0.0%	+9.4%	0.029%
1/24/2024	China Universal Asset Management Co. Ltd.	6,341	$89K	0.0%	N/A	0.012%
1/12/2024	SG Americas Securities LLC	15,874	$0.22M	0.0%	+38.1%	0.029%
12/19/2023	Public Employees Retirement System of Ohio	2,850	$35K	0.0%	N/A	0.005%
12/18/2023	Vanguard Group Inc.	1,710,307	$21.12M	0.0%	+2.2%	3.123%
12/1/2023	Wellington Management Group LLP	99,121	$1.22M	0.0%	+62.2%	0.181%
11/24/2023	EP Wealth Advisors LLC	46,248	$0.57M	0.0%	+831.1%	0.084%
11/22/2023	Polar Capital Holdings Plc	750,000	$9.26M	0.1%	N/A	1.369%
11/15/2023	GSA Capital Partners LLP	59,773	$0.74M	0.1%	-41.3%	0.145%
11/15/2023	Sectoral Asset Management Inc.	437,652	$5.41M	1.1%	-32.5%	1.058%
11/15/2023	Kynam Capital Management LP	235,176	$2.90M	0.5%	-82.0%	0.569%
11/15/2023	Acuta Capital Partners LLC	153,007	$1.89M	1.3%	+44.6%	0.370%
11/15/2023	Adage Capital Partners GP L.L.C.	388,982	$4.80M	0.0%	+68.1%	0.941%
11/14/2023	MPM Bioimpact LLC	1,857,681	$22.94M	6.1%	+301.7%	4.493%
11/14/2023	Schonfeld Strategic Advisors LLC	72,369	$0.89M	0.0%	-42.4%	0.175%
11/14/2023	Newtyn Management LLC	150,000	$1.85M	0.5%	-14.3%	0.363%
11/14/2023	Caxton Associates LP	13,474	$0.17M	0.0%	N/A	0.033%
11/13/2023	Algert Global LLC	47,630	$0.59M	0.0%	-18.0%	0.115%
11/13/2023	EAM Investors LLC	243,290	$3.01M	0.6%	+43.3%	0.588%
11/13/2023	Acadian Asset Management LLC	492,881	$6.09M	0.0%	-14.9%	1.192%
11/13/2023	ClariVest Asset Management LLC	65,900	$0.81M	0.0%	+23.9%	0.159%
11/13/2023	Silverarc Capital Management LLC	407,801	$5.04M	1.5%	+4.4%	0.986%
11/8/2023	Vivo Capital LLC	1,873,704	$23.14M	2.9%	+39.9%	4.531%
11/7/2023	New York State Common Retirement Fund	6,590	$81K	0.0%	-45.5%	0.016%
11/7/2023	Barclays PLC	4,657	$57K	0.0%	-13.0%	0.011%
11/6/2023	Victory Capital Management Inc.	63,450	$0.78M	0.0%	N/A	0.153%
10/24/2023	Raymond James Financial Services Advisors Inc.	13,287	$0.16M	0.0%	N/A	0.032%
10/24/2023	Raymond James & Associates	30,000	$0.37M	0.0%	N/A	0.073%
10/13/2023	SG Americas Securities LLC	11,495	$0.14M	0.0%	N/A	0.028%
10/11/2023	Vontobel Holding Ltd.	164,282	$2.03M	0.0%	-28.3%	0.397%

Data available starting January 2016

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Today's Range

Now: $8.78

$7.91

$8.90

50 Day Range

MA: $11.61

$7.87

$13.64

52 Week Range

Now: $8.78

$7.68

$16.77

Volume

1,206,240 shs

Average Volume

489,837 shs

Market Capitalization

$503.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.02

Who are the company insiders with the largest holdings of Olema Pharmaceuticals?: Olema Pharmaceuticals' top insider investors include:
Biocapital Advisors L Paradigm (Major Shareholder)
Bvf Partners L P/Il (Director)
G Walmsley Graham (Director)
Cyrus Harmon (Director)
David C Myles (Insider)
Sean Bohen (CEO)
Naseem Zojwalla (Insider)
Learn More about top insider investors at Olema Pharmaceuticals.
Who are the major institutional investors of Olema Pharmaceuticals?: Olema Pharmaceuticals' top institutional shareholders include:
Point72 Asset Management L.P. — 6.44%
State Street Corp — 3.44%
Wellington Management Group LLP — 1.75%
Great Point Partners LLC — 1.75%
Geode Capital Management LLC — 1.63%
Victory Capital Management Inc. — 1.49%
Learn More about top institutional investors of Olema Pharmaceuticals stock.
Which major investors are selling Olema Pharmaceuticals stock?: During the previous quarter, OLMA stock was sold by these institutional investors:
Geode Capital Management LLC
Janus Henderson Group PLC
HighVista Strategies LLC
Jacobs Levy Equity Management Inc.
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
Pitcairn Co.
Within the last year, company insiders that have sold Olema Pharmaceuticals company stock include:
Biocapital Advisors L Paradigm (Major Shareholder)
Bvf Partners L P/Il (Director)
Learn More investors selling Olema Pharmaceuticals stock.
Which major investors are buying Olema Pharmaceuticals stock?: In the previous quarter, OLMA stock was acquired by institutional investors including:
Point72 Asset Management L.P.
Charles Schwab Investment Management Inc.
Great Point Partners LLC
Wellington Management Group LLP
Ikarian Capital LLC
Victory Capital Management Inc.
Barclays PLC
Barclays PLC
Within the previous year, these company insiders have bought Olema Pharmaceuticals stock:
Biocapital Advisors L Paradigm (Major Shareholder)
Bvf Partners L P/Il (Director)
G Walmsley Graham (Director)
Learn More investors buying Olema Pharmaceuticals stock.

First JFK… next Elon?